Progyny (NASDAQ:PGNY) Updates Q4 2024 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its fourth quarter 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.310-0.350 for the period, compared to the consensus earnings per share estimate of 0.140. The company issued revenue guidance of $266.2 million-$281.2 million, compared to the consensus revenue estimate of $292.7 million. Progyny also updated its FY 2024 guidance to 1.540-1.570 EPS.

Progyny Trading Up 0.7 %

PGNY stock traded up $0.12 during mid-day trading on Tuesday, hitting $17.18. 1,996,870 shares of the company were exchanged, compared to its average volume of 1,371,571. The company has a market capitalization of $1.55 billion, a PE ratio of 27.27, a price-to-earnings-growth ratio of 1.57 and a beta of 1.44. Progyny has a twelve month low of $13.93 and a twelve month high of $42.08. The firm has a fifty day simple moving average of $18.01 and a 200 day simple moving average of $23.73.

Analyst Upgrades and Downgrades

PGNY has been the subject of several research reports. JMP Securities lowered shares of Progyny from an “outperform” rating to a “market perform” rating in a report on Thursday, September 19th. JPMorgan Chase & Co. decreased their price target on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, September 19th. Truist Financial decreased their price target on shares of Progyny from $33.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, September 19th. Canaccord Genuity Group decreased their price target on shares of Progyny from $24.00 to $18.00 and set a “hold” rating for the company in a report on Friday, September 20th. Finally, Jefferies Financial Group cut their price objective on shares of Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Progyny presently has an average rating of “Hold” and a consensus target price of $27.73.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.